New hope for aggressive brain cancer: drug duo tested in 90 patients

NCT ID NCT06336291

First seen Apr 25, 2026 · Last updated Apr 28, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs, L19TNF and lomustine, in 90 adults with glioblastoma that has come back or worsened. The goal is to find the safest and most effective dose by monitoring side effects and survival. Participants must have confirmed glioblastoma and a certain level of physical ability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute (DFCI)

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital (MGH)

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Virginia (UVA)

    Charlottesville, Virginia, 22903, United States

Conditions

Explore the condition pages connected to this study.